A Fortune Brands CEO, a PROCEPT President, and Five Biotech Specialists All Buy the Same Week: Operating Reality Is Running Ahead of the Fear Discount
Jesse Singh committed $2M of his own capital to Fortune Brands at $51 while Larry Wood made his first disclosed purchase at PROCEPT, both CEOs signaling that housing-adjacent demand and medtech adoption are stronger than public pricing admits. Simultaneously, five specialist biotech buyers across four names confirm that clinical pipelines are being priced at distress levels disconnected from what insiders see on the ground.



















